TAM/c-Met Inhibitor RXDX-106

Preferred Label : TAM/c-Met Inhibitor RXDX-106;

NCIt synonyms : TYRO3/AXL/MER/c-Met Inhibitor RXDX-106; N-[4-(6,7-Dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide;

NCIt related terms : CEP-40783;

NCIt definition : An orally available and selective inhibitor of the receptor tyrosine kinase (RTK) activity of both hepatocyte growth factor receptor (c-Met; HGFR) and receptors in the TYRO3, AXL, and MER (TAM) family, with potential immunomodulating and antineoplastic activities. Upon oral administration of TAM/c-Met inhibitor RXDX-106, this agent selectively targets and binds to TYRO3, AXL, MER and c-Met, and prevents their RTK activity. This blocks TYRO3/AXL/MER/c-Met-mediated signal transduction pathways, and inhibits the proliferation and migration of TYRO3-, AXL-, MER- and c-Met-overexpressing tumor cells. Inhibition of the TAM family in the tumor microenvironment (TME) activates the immune system in the TME, reverses TAM mediated immunosuppression and enhances the anti-tumor immune response, which lead to immune-mediated tumor cell killing. TYRO3, AXL and MER, members of the TAM family of RTKs, are overexpressed in many tumor cell types. TAMs play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis. c-Met, also overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. In the TME, TAM expression on immune cells contributes to tumor cell evasion of immune surveillance and to the negative regulation of immune responses.;

UNII : 1969ZJE05Q;

CAS number : 1437321-24-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1437321-24-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : CEP-40783; RXDX 106; CEP 40783; RXDX-106;

NCI Metathesaurus CUI : CL552337;

Details

Origin ID

C150585;

UMLS CUI

C4725852;

See also inter- (CISMeF)
- N-(4-(6,7-Dimethoxyquinolin-4-yl)oxy-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- RXDX-106 [MeSH Supplementary Concept]
chemical_or_drug_affects_gene_product
- Aurora Kinase A [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Hepatocyte Growth Factor Receptor [NCIt concept]
- Tyrosine-Protein Kinase Mer [NCIt concept]
- Tyrosine-Protein Kinase Receptor TYRO3 [NCIt concept]
- Tyrosine-Protein Kinase Receptor UFO [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients